SpringerLink
Log in

Pharmacokinetic Aspects of Drug-Drug and Drug-Plastic Interactions with Anticancer Drugs

  • Conference paper
Drug Delivery in Cancer Treatment II

Part of the book series: ESO Monographs ((ESO MONOGRAPHS))

Abstract

In order to achieve an optimal cytotoxic effect on various neoplasms, the concurrent administration of several anticancer drugs with different mechanisms of action has become routine today. Clinical practice also shows that combination drug therapy often seems to be more effective than single drug treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution

Subscribe and save

Springer+ Basic
EUR 32.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or Ebook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Chapter
EUR 29.95
Price includes VAT (France)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
EUR 85.59
Price includes VAT (France)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
EUR 105.49
Price includes VAT (France)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free ship** worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Similar content being viewed by others

References

  1. Balis FM: Pharmacokinetic drug interactions of commonly used anticancer drugs. Clin Pharmacokin 1986 (11):223–235

    Article  CAS  Google Scholar 

  2. Kuhlmann J, Zilly W and Wilke J: Effects of cytostatic drugs on plasma level and renal excretion of ß-acetyldigoxin. Clin Pharmacol Ther 1981 (30):518–527

    Article  PubMed  CAS  Google Scholar 

  3. Kuhlman J, Woodcock B, Wilke J and Rietbrock N: Verapamil plasma concentrations during treatment with cytostatic drugs. J Cardiovasc Pharmacol 1985 (7):1003–1006

    Article  Google Scholar 

  4. Bollini P, Riva R, Albani F, Ida N, Cacciari L, Bollini C and Baruzzi A: Decreased Phenytoin level during antineoplastic therapy: a case report. Epilepsia 1983 (24):75–78

    Google Scholar 

  5. Balis FM, Savitch JL and Bleyer WA: The pharmacokinetics of oral methotrexate in children. Cancer Res 1983 (43):23–45

    Google Scholar 

  6. Campbell MA, Perrier DG, Dorr RT, Alberts DS and Finley PR: Methotrexate: Bioavailability and pharmacokinetics. Cancer Treat Rep 1985 (69):833–838

    Google Scholar 

  7. Smith DK, Omura GA and Ostroy F: Clinical pharmacology of intermediate - dose oral methotrexate. Cancer Chemother Pharmacol 1980 (4):117–120

    Article  PubMed  CAS  Google Scholar 

  8. Pinkerton CR, Glasgow JFT, Welshman SG and Bridges JM: Can food influence the absorption of methotrexate in children with acute lymphoblastic leukemia? Lancet 1980 (2):944–946

    Article  PubMed  CAS  Google Scholar 

  9. Steel WH, Stuart JFB and Lawrence JR: Enhancement of methotrexate absorption by subdivision of dose. Cancer chemother Pharmacol 1979 (3):235–237

    Google Scholar 

  10. Shen DD and Azarnoff D: Clinical pharmacokinetics of methotrexate. Clin Pharmacokin 1978 (3):1–13

    Article  CAS  Google Scholar 

  11. Jaffe JH and Martin WR: Opoid analgesics and antagonists. In: Gilman AG, Goodman LS, Rail TW and Murad F (eds) The pharmacological basis of therapeutics. Macmillan Publishing Company New York, 1985 p 502

    Google Scholar 

  12. Gralla RJ, Itri LM, Pisko SE, Squillante AE and Kelsen DP: Antiemetic efficacy of high dose metoclopramide randomized trials with placebo and prochlorperazine in patients with chemotherapy-induced nausea and vomiting. New Engl J Med 1981 (305):905–909

    Google Scholar 

  13. Adair CG, Bridges JM and Desai ZR: Can food affect the bioavailability of chlorambucil in patients with haematological malignancies? Cancer Chemother Pharmacol 1986 (17):99–102

    Article  PubMed  CAS  Google Scholar 

  14. Ehrsson H, Wallin I, Simonsson B, Hartvig P and Oberg G: Effect of food on the pharmacokinetics of chlorambucil and its main metabolite, phenylacetic acid mustard. Eur J Clin Pharmacol 1984 (27):111

    PubMed  CAS  Google Scholar 

  15. Alberts DS, Chang SY, Chen HS, Evans TL and Moon TE: Oral melphalan kinetics: Clin Pharmacol Ther 1979 (26):737–745

    Google Scholar 

  16. Woodhouse KW, Hamilton P, Lennard A and Rawlins MD: The pharmacokinetics of melphalan in patients with multiple myeloma. Eur J Clin Pharmacol 1983 (24):283–285

    Article  PubMed  CAS  Google Scholar 

  17. Bosanquet AG: Stability of melphalan solutions during preparation and storage. J Pharm Sci 1985 (74):348–351

    Article  PubMed  CAS  Google Scholar 

  18. Sviland L, Robinson A, Proctor SJ and Bateman DN: Interaction of cimetidine with oral melphalan. A pharmacokinetic study. Cancer Chemother Pharmacol 1987 (20):173–175

    Google Scholar 

  19. Paalzow LK: How physiological and pathophysiological factors influence the pharmacokinetics and analgesic effect of opiates in cancer patients. In: Domellof L (ed) Drug delivery in cancer treatment. Springer-Verlag Berlin Heidelberg 1987 pp 19–27

    Google Scholar 

  20. Zimm S, Collins JM, O’Neill D, Chabner BA and Poplack DG: Inhibition of first-pass metabolism in cancer chemotherapy: Interaction of 6-mercaptopurine and allopurinol. Clin Pharmacol Ther 1983 (34): 810–817

    Google Scholar 

  21. Elion GB: Biochemistry and pharmacology of purine analogues. Fed Proc 1967 (26):898–904

    PubMed  CAS  Google Scholar 

  22. Poplack DG, Balis FM and Zimm S: The pharmacology of orally administered chemotherapy. Cancer 1986 (Suppl July 15 ): 473–480

    Google Scholar 

  23. Riccardi R, Balis F, Ferrara P, Lasorella A, Poplack D and Mastrangelo R: Influence of food intake on the absorption of orally administered 6-mercaptopurine (6-MP). Proc Am Soc Clin Oncol 1985 (4):34

    Google Scholar 

  24. Balis FM, Holcenberg JS, Zimm S, Tubergen D, Collins JM, Murphy RF, Gilchrist GS, Hammond D and Poplack DG: The effect of methotrexate on the bioavailability of oral 6-mercaptopurine. Clin Pharmacol Ther 1987 (41):384–387

    Google Scholar 

  25. Sitar DS, Shaw DH, Thirwell MP and Rendy JR: Disposition of 5-fluorouracil after intravenous bolus doses of a commerical formulation to cancer patients. Cancer Res 1977 (37):3981–3984

    PubMed  CAS  Google Scholar 

  26. Finn C and Sadee W: Determination of 5-fluorouracil (NSC-19893) plasma levels in rats and man by isotope dilution-mass fragmentography. Cancer Chemother Rep 1975 (59):279–286

    CAS  Google Scholar 

  27. Balis FM, Holcenberg JS and Bleyer WA: Clinical pharmacokinetics of commonly used anticancer drugs. Clin Pharmacokin 1983 (8):202–232

    Article  CAS  Google Scholar 

  28. Christophidis N, Vajda FJE, Lucus J, Drummer O, Moon WJ and Louis WJ: Fluorouracil therapy in patients with carcinoma of the large bowel: a pharmacokinetic comparison of various rates and routes of administration. Clin Pharmacokin 1978 (3):330–336

    Google Scholar 

  29. Harvey VJ, Slevin ML, Dilloway MR, Clark PJ and Johnston A: The influence of cimetidine on the pharmacokinetics of 5-fluorouracil. Brit J Clin Pharmacol 1984 (18):421–430

    Google Scholar 

  30. Rowland M and Tozer TN: Distribution. In: Clinical Pharmacokinetics: concepts and applications. Lea & Febiger, Philadelphia 1980 pp 34–47

    Google Scholar 

  31. Schiffman FJ, Uehara Y, Fisher JM and Rabinovitz M: Potentiation of chlorambucil activity by phenylbutazone. Cancer Letters 1978 (4):211–216

    Article  PubMed  CAS  Google Scholar 

  32. Evans WE and Christensen ML: Drug interactions with methotrexate. J Rheumatol 1985 (suppl 12)12):15–20

    CAS  Google Scholar 

  33. Nelson RL, Dyke RW and Root MA: Comparative pharmacokinetics of vindesine, vincristine and vinblastine in patients with cancer. Cancer Treatm Rev 7 1980 (suppl): 17–24

    Article  Google Scholar 

  34. DeConti RC, Toftness BR, Lange RC and Creasy WA: Clinical and pharmacological studies with cisdiamminedichloroplatinum II. Cancer Res 1973 (33):1310–1315

    Google Scholar 

  35. LeRoy AF, Lutz RJ, Dedrik RL, Litterst CL and Guarino AM: Pharmacokinetic study of cis-dichlorodiammineplatinum (ll)(DDP) in the beagle dog: thermodynamic and kinetic behaviour of DDP in a biologic milieu. Cancer Treatm Rep 1979 (63):59–71

    Google Scholar 

  36. Pfeifle CF, Howell SB, Felthouse RD, Woliver TBS and Andrews PA: High dose cisplatin with sodium thiosulphate protection. J Clin Oncol 1985 (3):237–244

    PubMed  CAS  Google Scholar 

  37. Evans WE, Crom WR, Abromovitch M, Dodge R, Look AT, Bowman WP, George SL and Pui CH: Clinical pharmacodynamics of high-dose methotrexate in acute lymphocytic leukemia. New Eng J Med 1986 (314):471–477

    Google Scholar 

  38. Grochow LB and Colvin M: Clinical pharmacokinetics of cyclophosphamide. Clin Pharmacokin 1979 (4):380–394

    Article  CAS  Google Scholar 

  39. Fao JY, Fusko WJ and Cohen JL: Phenobarbital effects on cyclophosphamide pharmacokinetics in man. Cancer Res 1972 (32):2761–2764

    Google Scholar 

  40. D’Incalci M, Bolis G, Facchinetti T, Mangioni C and Morasca L: Decreased half life of cyclophosphamide in patients under continual treatment. Europ J Cancer 1979 (15):7–10

    Google Scholar 

  41. Graham MI, Shaw IC, Souhami RL, Sidau B and Harper PG: Decreased plasma half-life of cyclophosphamide during repeated high-dose administration. Cancer Chemother and Pharmacol 1983 (10):192–193

    CAS  Google Scholar 

  42. Sladck NE, Priest J, Doeden D, Mirocha CJ and Pathre S: Plasma half-life and urinary excretion of cyclophosphamide in children. Cancer Treatm Rep 1980 (64):1061–1066

    Google Scholar 

  43. Bagley CM, Bostich FW and De Vita VT: Clinical pharmacology of cyclophosphamide. Cancer Res 1973 (33):226–233

    PubMed  Google Scholar 

  44. Mouridsen HT, Faber O and Skovsted L: The metabolism of cyclophosphamide. Cancer 1976 (37):665–670

    Article  PubMed  CAS  Google Scholar 

  45. Dorr DI and Alberts DS: Cimetidine enhancement of cyclophosphamide antitumor activity. Br J Cancer 1982 (45):35–43

    Article  PubMed  CAS  Google Scholar 

  46. Collins JM, Dedrik RL, King FG, Speyer JL and Myers CE: Nonlinear pharmacokinetic models for 5-flurouracil in man: intravenous and intraperitoneal routes. Clin Pharmacol Ther 1980 (28):235–246

    Google Scholar 

  47. Au JL-S, Rustum YM, Ledesma EJ, Mittelman A and Creaven PJ: Clinical pharmacological studies of concurrent infusion of 5-fluorouracil and thymidine in treatment of colorectal carcinomas. Cancer Res 1982 (42):2930–2937

    Google Scholar 

  48. Mc Dermott BJ, Van der Berg HW, Martin WMC and Murphy RF: Pharmacokinetic rationale for the interaction of 5-fluorouracil and misonidazole in humans. Br J Cancer 1983 (48):705–710

    Article  CAS  Google Scholar 

  49. Bertino JR: Toward improved selectivity in cancer chemotherapy. Cancer Res 1979 (39):293–304

    PubMed  CAS  Google Scholar 

  50. Evans WE, Crom WR, Sinjule JA, Yee GC and Stewart CF: Pharmacokinetics of anticancer drugs in children. Drug Metabol Rew 1983 (14): 847–886

    Google Scholar 

  51. Juma FD, Rogers HJ and Trounce JR: Pharmacokinetics of cyclophosphamide and alkylating activity in man after intravenous and oral administration. Br J Clin Pharmacol 1979 (8):209–217

    PubMed  CAS  Google Scholar 

  52. Mouridsen HT and Jacobsen E: Pharmacokinetics of cyclophosphamide in renal failure. Acta Pharmacol et Tox 1975 (36):409–414

    Article  CAS  Google Scholar 

  53. Bagley CM, Bostich FW and De Vita VT: Clinical pharmacology of cyclophosphamide. Cancer Res 1973 (33):226–233

    Google Scholar 

  54. Witten S, Frederiksen PL and Mouridsen HT: The pharmacokinetics of cyclophosphamide in man after treatment with allopurinol. Acta Pharmacol et Tox 1980 (46):392–394

    Article  CAS  Google Scholar 

  55. Aherne GW, Piall E, Marks V, Mould G and White WF: Prolongation and enhancement of serum methotrexate concentrations by probenecid. Br Med J 1978 (1):1097–1099

    Article  PubMed  CAS  Google Scholar 

  56. Howell SB, Olshen RA and Rice JA: Effect of probenecid on cerebrospinal fluid methotrexate kinetics. Clin Pharmacol Ther 1979 (26): 641–646

    PubMed  CAS  Google Scholar 

  57. Liegler DG, Henderson ES, Hahn MA and Oliverio VT: The effect of organic acids on renal clearance of methotrexate in man. Clin Pharmacol Ther 1969 (10):849–857

    Google Scholar 

  58. Williams WM, Chen TS and Huang KC: Effect of pencillin on the renal tubular secretion of methotrexate in the monkey. Cancer Res 1984 (44):1913–1917

    PubMed  CAS  Google Scholar 

  59. Mandel MA: The synergistic effect of salicylates on methotrexate toxicity. Plastic and Reconstructive Surg 1976 (57):733–739

    Article  CAS  Google Scholar 

  60. Thyss A, Milano G, Kubar J, Namer M and Schneider M: Clinical and pharmacokinetic evidence of a life treatening interaction between methotrexate and ketoprofen. Lancet 1986 (1):256–258

    Google Scholar 

  61. Ellison NM and Servi RJ: Acute renal failure and death following sequential intermediate-dose methotrexate and 5-FU: a possible adverse effect due to concomitant indomethacin administration. Cancer Treatm Rep 1985 (69):342–343

    CAS  Google Scholar 

  62. Maiche AG: Acute renal failure due to concomitant action of methotrexate and indomethacin. Lancet 1986 (1): 1390

    Article  PubMed  CAS  Google Scholar 

  63. Singh RR, Malaviya AN, Pandey JN and Guleria JS: Fatal interaction between methotrexate and naproxen. Lancet 1986 (1): 1390

    Google Scholar 

  64. Daly H, Boyle J, Roberts C and Scott G: Interaction between methotrexate and non-steroidal antiinflammatory drugs. Lancet 1986 (1): 557

    Article  PubMed  CAS  Google Scholar 

  65. Ng HWK, MacFarlane AW, Graham RM and Verbov JL: Near fatal drug interactions with methotrexate given for psoriasis. Br Med J 1987 (295):752–753

    Google Scholar 

  66. Thomas MH and Gutterman LA: Methotrexate toxicity in a patient receiving trimethoprim- sulphamethoxazole. J Reumatol 1986 (13): 440–441

    CAS  Google Scholar 

  67. Paxton JW: The protein binding and elimination of methotrexate after intravenous infusions in cancer patients. Clin Exp Pharmacol Physiol 1982 (9): 225–234

    Article  PubMed  CAS  Google Scholar 

  68. Dettli L: Pharmacokinetic aspects of drug interactions. In: Cluff LE and Petric JC (eds) Clinical effects of interaction between drugs. Elsevier, New York 1974 pp 39–68

    Google Scholar 

  69. Slordal L, Sager G and Aarbakke J: Pharmacokinetic interactions with methotrexate: is 7-hydroxy- methotrexate the culprit? Lancet1988 (1):591–592

    Article  PubMed  CAS  Google Scholar 

  70. Jacobs SA, Stoller RG, Chabner BA and Johns DG: 7-Hydroxy-methotrexate as a urinary metabolite in human subjects and rhesus monkeys receiving high- dose methotrexate. J Clin Invest 1976 (57):534–538

    Google Scholar 

  71. Crom WR, Pratt CB, Green AA, Campion JE and Crom DB: The effects of prior cisplatin therapy on the pharmacokinetics of high-dose methotrexate. J Clin Oncol 1984 (2):655–661

    Google Scholar 

  72. Haim N, Kedar A and Robinson E: Methotrexate-related deaths in patients previously treated with cis-diammine dichloride platinum. Cancer Chem and Pharmacol 1984 (13):223–225

    Article  CAS  Google Scholar 

  73. Schentag JJ, Plant ME and Cerra FB: Aminoglycoside nephrotoxicity in critically ill surgical patients. J Surg Res 1979 (26):270–279

    Google Scholar 

  74. Smith CR, Maxwell RR and Edward CQ: Nephrotoxicity induced by gentamicin and amikacin. John Hopkins Med J 1978 (142):85–90

    CAS  Google Scholar 

  75. Bennett WM, Pastore L and Houghton DC: Fatal pulmonary toxicity in cisplatin-induced acute renal failure. Cancer Treatm Rep 1980 (64): 921–924

    CAS  Google Scholar 

  76. Perry DJ, Weiss RB and Taylor HG: Enhanced bleomycin toxicity during acute renal failure. Cancer Treatm Rep 1982 (66):592–593

    Google Scholar 

  77. Yee GC, Crom WR, Campion JE, Brodeur GM and Evans WE: Cisplatin-induced changes in bleomycin elimination. Cancer Treatm Rep 1983 (67):587–589

    Google Scholar 

  78. Smith PHS and Taylor DM: Distribution and retention of the antitumor agent 195m-Pt-cis- dichlorodiammine platinum (II) in man. J Nucl Med 1974 (15):349–351

    PubMed  CAS  Google Scholar 

  79. Jacobs C, Coleman CN, Rich L, Hirst K and Weiner MW: Inhibition of cis-diamminedichloroplatinum secretion by the human kidney with probenecid. Cancer Res 1984 (44):3632–3635

    PubMed  CAS  Google Scholar 

  80. Fredriksson K, Lundgren P and Landersjö L: Stability of carmustine kinetics and compatibility during administration. Acta Pharm Suec 1986 (23):115–124

    PubMed  CAS  Google Scholar 

  81. Benvenuto JA, Andersson RW, Kerhof K, Smith RG and Loo TL: Stability and compatibility of antitumor agents in glass and plastic containers. Am J Hosp Pharm 1981 (38):1914–1918

    Google Scholar 

  82. Biondi L and Nairn JG: Stability of 5-Fluorouracil and flucytosine in parenteral solutions. The Can J Hosp Pharm 1986 (39):60–64

    Google Scholar 

  83. De Luca PP: Binding of drugs to inline filters. Am J Hosp Pharm 1979 (36):151–154

    Google Scholar 

  84. Butler LD, Munson JM and De Luca PP: Effect of inline filtration on the potency of low-dose drugs. Am J Hosp Pharm 1980 (37):935–941

    PubMed  CAS  Google Scholar 

  85. Kanke M, Eubanks JL and De Luca PP: Binding of selected drugs to a “treated” inline filter. Am J Hosp Pharm 1983 (40):1323–1328

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Biopharmaceutics and Pharmacokinetics, University of Uppsala, Uppsala, Sweden

    Lennart K. Paalzow

Authors
  1. Lennart K. Paalzow
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Department of Surgery, Regional Hospital, 70185, Örebro, Sweden

    Lennart Domellöf

Rights and permissions

Reprints and permissions

Copyright information

© 1989 Springer-Verlag Berlin Heidelberg

About this paper

Cite this paper

Paalzow, L.K. (1989). Pharmacokinetic Aspects of Drug-Drug and Drug-Plastic Interactions with Anticancer Drugs. In: Domellöf, L. (eds) Drug Delivery in Cancer Treatment II. ESO Monographs. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-74709-0_3

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-74709-0_3

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-74711-3

  • Online ISBN: 978-3-642-74709-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation